Recruiting studies: Mild Autonomous Cortisol Secretion Macs

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Phase 2 · 1 location(s) · Mayo Clinic · NCT07104812 New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of MACS
Phase N/A · 1 location(s) · University Hospital, Bordeaux · NCT07352527 Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
Phase 4 · 1 location(s) · Laikο General Hospital, Athens · NCT07268222 Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Phase N/A · 1 location(s) · Mayo Clinic · NCT04543253 Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Phase 4 · 1 location(s) · Johns Hopkins University · NCT07247058 IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
NA · 1 location(s) · University of Texas Southwestern Medical Center · NCT07361874 Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
Phase N/A · 1 location(s) · The Cleveland Clinic · NCT06344143

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.